Promoting competition among new drugs does not necessarily mean encouraging development of so-called "me-too" products and the limited band-width of FDA's document redaction effort may mean the release of complete response letters is not prioritized, FDA Commissioner Scott Gottlieb told the Pink Sheet in a recent interview.
Gottlieb spoke Nov. 3 at the National Press Club in Washington, D.C. (Also see "Gottlieb Promotes 'Team' Work For...






